Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Maastricht – page 40

1 387 clinical trials in Maastricht, The Netherlands across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Maastricht at a glance
1 387
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 387 trials in Maastricht

Open in trial search

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Universitaetsklinikum Essen AöR

Long-Term Safety Study of BCMACP03, BCN-CP01, and 19CP02 for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, CLL, SLL, or Multiple Myeloma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Galapagos

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study on Fludarabine, Melphalan, and ATG for Patients with Blood Cancer Undergoing Reduced Intensity Stem Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Melphalan
  • Sponsor:Universitair Ziekenhuis Gent

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Karolinska Institutet

Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:Universitair Medisch Centrum Utrecht

Study on Treating Resistant Viral Infections in Stem Cell Transplant Patients Using Allogeneic Multivirus-Specific T Cells

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Medical Center - University Of Freiburg

Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on the Safety and Effects of Lutetium (177Lu) rhPSMA-10.1 Injection in Men with Advanced Prostate Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:177Lu-Rhpsma-10.1
  • Sponsor:Blue Earth Therapeutics Limited

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Flixebrutinib
  • Sponsor:Telios Pharma Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Maastricht

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer, and melanoma treatments. Studies include novel therapy combinations and personalized treatment approaches.

  • Advanced treatment protocols for metastatic conditions
  • Immunotherapy interventions
  • Diagnostic imaging improvements

Particular emphasis on targeted therapies and treatment optimization for various cancer types.

02 Chronic Disease Management

Research focusing on chronic kidney disease, fibromyalgia, and inflammatory bowel conditions. Studies evaluate new therapeutic approaches and treatment combinations.

  • Novel drug combinations
  • Disease progression monitoring
  • Quality of life improvements

Emphasis on developing effective long-term management strategies for chronic conditions.

03 Cardiovascular Studies

Investigations into peripheral arterial disease and cardiomyopathy treatments. Research includes innovative therapeutic approaches and preventive strategies.

  • Cardiovascular risk reduction
  • Treatment optimization
  • Disease prevention protocols

Focus on improving patient outcomes through targeted interventions and preventive measures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.